SCOTTSDALE, Ariz., March 11 /PRNewswire/ -- Makers of a new liquid natural supplement formulation of Cetyl-Myristoleate (CMO) are seeking osteoarthritis and fibromyalgia patients for a pilot study in Phoenix beginning Monday, April 12, 2010. The new formulation, developed by Arizona nutraceutical company, Liquid CMO, LLC, has produced remarkable testimonial results with no harmful side effects and no known drug interactions and is looking to document elimination of symptoms. For more information visit www.liquidcmo.com or call (877) 734–4261.
Pilot study participants will have the opportunity to benefit from the positive effects current users of the supplement have experienced in last two years of human trials, while taking the newest Liquid CMO formulation. All participants will be medically supervised by David Arneson, NMD, medical director of The Source Naturopathic Medical Clinic, 550 W. Indian School Rd., #122 Phoenix, AZ 85013. Pilot study information can be downloaded from www.liquidcmo.com.
Cetyl-Myristoleate is a naturally ring waxy alcohol (Long Chain Fatty Acid) discovered in 1972 by Dr. Harry Diehl. Dr. Diehl applied for and received two U.S. Patents on cetyl myristoleate, the first in 1977 for the treatment of rheumatoid arthritis and then in 1996 for osteoarthritis.
CMO has been found through clinical studies and client testimonies to benefit many with autoimmune diseases such as osteoarthritis, rheumatoid arthritis, fibromyalgia, lupus, Crohn's disease, Sjogren's syndrome and multiple sclerosis. According to personal accounts by current Liquid CMO users, stiffness, pain and swollen joints have decreased or vanished.
Liquid CMO Pilot Study Parameters:
Liquid CMO is manufactured in the USA at a National Science Foundation (NSF) registered and certified facility. For more information or to participate in pilot study visit www.liquidcmo.com or call (877) 734–4261 or email [email protected].
SOURCE Liquid CMO, LLC
Advertisement
Pilot study participants will have the opportunity to benefit from the positive effects current users of the supplement have experienced in last two years of human trials, while taking the newest Liquid CMO formulation. All participants will be medically supervised by David Arneson, NMD, medical director of The Source Naturopathic Medical Clinic, 550 W. Indian School Rd., #122 Phoenix, AZ 85013. Pilot study information can be downloaded from www.liquidcmo.com.
Advertisement
Cetyl-Myristoleate is a naturally ring waxy alcohol (Long Chain Fatty Acid) discovered in 1972 by Dr. Harry Diehl. Dr. Diehl applied for and received two U.S. Patents on cetyl myristoleate, the first in 1977 for the treatment of rheumatoid arthritis and then in 1996 for osteoarthritis.
CMO has been found through clinical studies and client testimonies to benefit many with autoimmune diseases such as osteoarthritis, rheumatoid arthritis, fibromyalgia, lupus, Crohn's disease, Sjogren's syndrome and multiple sclerosis. According to personal accounts by current Liquid CMO users, stiffness, pain and swollen joints have decreased or vanished.
Liquid CMO Pilot Study Parameters:
- Effects on symptoms for Osteoarthritis and Fibromyalgia, 65 participants each.
- Study is four consecutive weeks from initial visit and evaluation.
- Participant must complete initial questionnaire.
- Participant will schedule initial 20 minute office visit with naturopathic doctor and be seen weekly at no charge to evaluate and document progress until study completed.
- Participants will be unpaid in an effort to remain independent, and required to purchase the first bottle of Liquid CMO, a 2-weeks supply, for $92.00. The second two-week supply is provided at no charge.
Liquid CMO is manufactured in the USA at a National Science Foundation (NSF) registered and certified facility. For more information or to participate in pilot study visit www.liquidcmo.com or call (877) 734–4261 or email [email protected].
SOURCE Liquid CMO, LLC
